Close Menu

Harvard

American researchers reported today they have identified microRNA-mediated interactions between coding and non-coding messenger RNAs.

The CNV assays are the latest effort by NanoString to ferret out new applications for its nCounter platform, which the company initially developed as an alternative to both qPCR and microarrays for gene expression studies.

Co-founded by Harvard physics professor David Weitz, a founder of RainDance Technologies, the startup plans to develop an inexpensive, fast, and scalable microfluidics-based sequencer, where reactions take place in picoliter-sized drops.

For early adopters, there are many reasons to be excited about the potential of whole-genome sequencing to broadly personalize healthcare. But for some public health observers, the analytical and educational challenges present an overwhelming hurdle.

By sequencing the Neandertal nuclear genome and comparing it with human and chimpanzee genomes, an international research team has gained new insights into the histories of both humans and Neandertals.

Researchers from Stanford and Harvard Universities reported today that they have scoured an individual's whole-genome sequence for clinically useful information.

Since a US federal district court last month deemed seven of Myriad Genetics' BRCA patents invalid, certain industry players have taken small steps toward fostering more collaboration around gene patents while others have raised questions about the value of patenting genes altogether amid rapid advances in whole-genome sequencing.

Pairings: Apr 28, 2010

Premium

Raju Kucherlapati, Ardy Arianpour

Foundation Medicine has raised $25 million in Series A financing that it will use to "broadly analyze the relevant tumor genomic and other molecular information in individual patients' cancers and connect it with a knowledgebase of clinical data to help oncologists personalize treatment."

In a newsletter published last week, PGP organizers said they have now started to enroll participants for the PGP-100. Enrollment for the next phase of the project, PGP-1000, is expected to start later this year.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.